-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Edited and sorted out by Yimaitong, please do not reprint
without authorization.
The 2022 European Society for Internal Oncology (ESMO) Annual Meeting will be held
in Paris from September 9 to 13 local time.
background
The combination regimen of pabolizumab and axitinib (PAXI) is approved as a first-line treatment
for metastatic renal cell carcinoma (mRCC).
method
The ProPAXI study was a multicenter, prospective study that included Italian patients
diagnosed with mRCC who received PAXI as a first-line treatment.
outcome
Between January 2021 and April 2022, a total of 96 patients
were included in the study.
At the time of the analysis, 70% of patients were still receiving treatment, and 65% of patients were still receiving pabolizumab and axitinib
.
About half (57%) of patients experienced clinically significant adverse events (AEs) defined as events
that led to the need for corticosteroids (29%), hormone replacement (11%), delayed use (71%), discontinuation (16%), and dose reduction (36%).
References:
A.
Guida, et al.
Efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study).
2022 ESMO.
Abstract 1469P.
